Skip to main content

The Eshelman Institute for Innovation has announced the recipients of its 2023 therapeutics grant cycle. The Eshelman Institute was established in 2014 with a $100 million commitment from Fred Eshelman, PharmD. The institute provides grant funding, project management support, competitive landscape analysis, the path to market assistance and capital investment connections to faculty and staff across UNC-Chapel Hill.

The Eshelman Institute works with Carolina faculty who are collaborating with scientists and health care providers both inside and outside UNC-Chapel Hill, including academia, industry and foundations.

This past winter the Eshelman Institute ran their annual therapeutic grant RFP, and have now selected their grant recipients. To learn more about these projects, please visit this website.

2023 Grant Recipients:

T Cell Immunotherapies Targeting HLA-E Antigens for the Clearance of EBV- and HTLV-Associated Malignancies

Paul Armistead, MD, PhD

UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center

Nilu Goonetilleke, PhD

UNC School of Medicine, Microbiology and Immunology

Inhibiting Aquaporin-4: A New Approach for the Treatment of Stroke and CNS Injuries

Kevin Frankowski, PhD

UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery

Rosyln Bill, PhD

Aston University, College of Health & Life Sciences

Follow on Funding: Development of Novel Therapeutics for Multiple Myeloma

Lindsey James, PhD

UNC Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry

Restoring Lysosome Function Using a Therapeutic Antibody to Prevent Disease Flare in Systemic Lupus Erythematosus

Barbara Vilen, PhD

UNC School of Medicine, Department of Microbiology and Immunology

Anyone interested in learning more about the Eshelman Institute can email